NCT06635954 A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
| NCT ID | NCT06635954 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oxford Biodynamics Inc. |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-05-14 |
| Primary Completion | 2026-05-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2024-05-14 with a primary completion date of 2026-05-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age or older 2. Stage III or IV cancer 3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice. 4. ECOG performance status ≤ 2 5. Clinically eligible for ICI therapy 6. Able to read, understand and provide written informed consent. 7. Willing and able to comply with the study requirements Exclusion Criteria: 1. Pregnant or breastfeeding 2. History of bone marrow or organ transplant 3. Contra indication for receiving Immune Check Point inhibitor.
Contact & Investigator
Ryan Mathis, MD
STUDY DIRECTOR
Oxford BioDynamics
Frequently Asked Questions
Who can join the NCT06635954 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06635954 currently recruiting?
Yes, NCT06635954 is actively recruiting participants. Contact the research team at ryan.mathis@myobdx.com for enrollment information.
Where is the NCT06635954 trial being conducted?
This trial is being conducted at Norwich, United States, Dublin, United States, Rock Hill, United States.
Who is sponsoring the NCT06635954 clinical trial?
NCT06635954 is sponsored by Oxford Biodynamics Inc.. The principal investigator is Ryan Mathis, MD at Oxford BioDynamics. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.